Literature DB >> 2205398

Distinct classes of transcriptional activating domains function by different mechanisms.

D Tasset1, L Tora, C Fromental, E Scheer, P Chambon.   

Abstract

We have previously shown that the two transcriptional activation functions (TAF-1 and TAF-2) of the human estrogen receptor (hER) have synergistic properties different from one another and from those of acidic activating domains (AADs). Here we compare the transcriptional interference/squelching properties of the hER TAFs with those of the AADs of yeast GAL4 and chimeric GAL-VP16 activators. Our results indicate that AADs interact with a factor(s) that, while required for activation by AADs, is not essential for activation by hER TAFs. In contrast, hER TAFs appear to interact with factors indispensable for mediating both their activation function and that of AADs. Thus, different classes of trans-activators may interact with different factors. In addition, the synergistic and transcriptional interference/squelching properties of the two TAFs of the human glucocorticoid receptor (hGR) indicate that both are composed of acidic and nonacidic activation functions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2205398     DOI: 10.1016/0092-8674(90)90394-t

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  113 in total

1.  Sp100 interacts with ETS-1 and stimulates its transcriptional activity.

Authors:  Christine Wasylyk; Sophie E Schlumberger; Paola Criqui-Filipe; Bohdan Wasylyk
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

2.  Steroid receptor induction of gene transcription: a two-step model.

Authors:  G Jenster; T E Spencer; M M Burcin; S Y Tsai; M J Tsai; B W O'Malley
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

3.  Differential modes of activation define orphan subclasses within the steroid/thyroid receptor superfamily.

Authors:  J P Lydon; R F Power; O M Conneely
Journal:  Gene Expr       Date:  1992

4.  Antiestrogen can establish nonproductive receptor complexes and alter chromatin structure at target enhancers.

Authors:  T A Pham; J F Elliston; Z Nawaz; D P McDonnell; M J Tsai; B W O'Malley
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

5.  Synergistic transcriptional activation by CTF/NF-I and the estrogen receptor involves stabilized interactions with a limiting target factor.

Authors:  E Martinez; Y Dusserre; W Wahli; N Mermod
Journal:  Mol Cell Biol       Date:  1991-06       Impact factor: 4.272

6.  An indirect negative autoregulatory mechanism involved in hepatocyte nuclear factor-1 gene expression.

Authors:  A A Kritis; E Ktistaki; D Barda; V I Zannis; I Talianidis
Journal:  Nucleic Acids Res       Date:  1993-12-25       Impact factor: 16.971

7.  A cell-specific factor represses stimulation of transcription in vitro by transcriptional enhancer factor 1.

Authors:  S Chaudhary; C Brou; M E Valentin; N Burton; L Tora; P Chambon; I Davidson
Journal:  Mol Cell Biol       Date:  1994-08       Impact factor: 4.272

8.  Protein and DNA elements involved in transactivation of the promoter of the bovine herpesvirus (BHV) 1 IE-1 transcription unit by the BHV alpha gene trans-inducing factor.

Authors:  V Misra; A C Bratanich; D Carpenter; P O'Hare
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

9.  The role of activation functions 1 and 2 of estrogen receptor-α for the effects of estradiol and selective estrogen receptor modulators in male mice.

Authors:  Anna E Börjesson; Helen H Farman; Cecilia Engdahl; Antti Koskela; Klara Sjögren; Jenny M Kindblom; Alexandra Stubelius; Ulrika Islander; Hans Carlsten; Maria Cristina Antal; Andrée Krust; Pierre Chambon; Juha Tuukkanen; Marie K Lagerquist; Sara H Windahl; Claes Ohlsson
Journal:  J Bone Miner Res       Date:  2013-05       Impact factor: 6.741

Review 10.  Nuclear receptors in bone physiology and diseases.

Authors:  Yuuki Imai; Min-Young Youn; Kazuki Inoue; Ichiro Takada; Alexander Kouzmenko; Shigeaki Kato
Journal:  Physiol Rev       Date:  2013-04       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.